We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Two PARP Family Enzymes Cross-Regulate Macrophage Activation

By LabMedica International staff writers
Posted on 09 Nov 2016
Two of the PARP (poly(ADP-ribose) polymerase) family of enzymes have been identified as being key regulators of the type of macrophage activation that has been linked to development of atherosclerosis.

PARP enzymes are essential in a number of cellular functions, including expression of inflammatory genes. More...
This protein is found in the nucleus of cells where its primary function is to detect and signal single-strand DNA breaks (SSB) to the enzyme mechanisms involved in SSB repair. PARP activation is an immediate cellular response to metabolic, chemical, or radiation-induced DNA SSB damage. Once PARP detects a SSB, it binds to the DNA, and, after a structural change, begins the synthesis of a poly (ADP-ribose) (PAR) chain as a signal for the other DNA-repairing enzymes. After completing the repair, the PAR chains are degraded via poly (ADP-ribose) glycohydrolase (PARG).

Investigators at Brigham and Women's Hospital (Boston, MA, USA) employed advanced proteomic techniques to screen a large number of molecules for their effect on macrophage activation. They reported in the October 31, 2016, online edition of the journal Nature Communications that two members of the PARP family, PARP9 and PARP14, were regulators of macrophage activation, which has been linked to arterial disease by systems biology.

In primary macrophages, PARP9 and PARP14 had opposing roles in macrophage activation. PARP14 silencing induced pro-inflammatory genes and STAT1 phosphorylation in M(interferon-gamma) cells, whereas it suppressed anti-inflammatory gene expression and STAT6 phosphorylation in M(IL-4) cells. PARP9 silencing suppressed pro-inflammatory genes and STAT1 phosphorylation in M(interferon-gamma) cells. PARP14 induced ADP-ribosylation of STAT1, which was suppressed by PARP9. These findings suggested that PARP9 and PARP14 cross-regulated macrophage activation.

"Macrophage activation plays a role in not only vascular disorders but also various inflammatory and autoimmune diseases," said senior author Dr. Masanori Aikawa, director of the center for interdisciplinary cardiovascular sciences at Brigham and Women's Hospital. "These results could provide important information about the mechanisms of these diseases and help to develop much needed new therapeutics."

Related Links:
Brigham and Women's Hospital



Gold Member
Blood Gas Analyzer
Stat Profile pHOx
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Automated MALDI-TOF MS System
EXS 3000
HBV DNA Test
GENERIC HBV VIRAL LOAD VER 2.0
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Immunology

view channel
Image: Circulating tumor cells isolated from blood samples could help guide immunotherapy decisions (Photo courtesy of Shutterstock)

Blood Test Identifies Lung Cancer Patients Who Can Benefit from Immunotherapy Drug

Small cell lung cancer (SCLC) is an aggressive disease with limited treatment options, and even newly approved immunotherapies do not benefit all patients. While immunotherapy can extend survival for some,... Read more

Industry

view channel
Image: The LIAISON NES molecular point-of-care platform (Photo courtesy of Diasorin)

Diasorin and Fisher Scientific Enter into US Distribution Agreement for Molecular POC Platform

Diasorin (Saluggia, Italy) has entered into an exclusive distribution agreement with Fisher Scientific, part of Thermo Fisher Scientific (Waltham, MA, USA), for the LIAISON NES molecular point-of-care... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.